23 Jul Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof
Abstract
The invention belongs to the technical field of biological genetic engineering and particularly discloses design, a preparation method and pharmaceutical application of a tumor targeting tumor necrosis factor related apoptosis ligand variant. The tumor targeting tumor necrosis factor related apoptosis ligand variant is fusion protein composed by ligand, connecting peptide and tumor necrosis factor related apoptosis ligand of CD13 and is produced through cloning and constructing of coding genes of the variant, soluble recombination expression and simple separation and purification in a genetic engineering method. The variant generated by the preparation method of the tumor targeting tumor necrosis factor related apoptosis ligand variant has good tumor tissue targeting property, remarkably enhances antitumous effect, can reduce protein administration dosage required for obtaining therapeutic effect, improves bioavailability, lowers treatment cost, and eliminates potential toxic and side effect of the tumor necrosis factor related apoptosis ligand. Simultaneously, the manufacturing method of the tumor targeting tumor necrosis factor related apoptosis ligand variant provides an expression method for producing soluble high-polymer form content and a simple separation and purification process.
Year: 2013
Country: CN
Doc No: 102863537